Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2008

Open Access 01-12-2008 | Review

Congenital long QT syndrome

Authors: Lia Crotti, Giuseppe Celano, Federica Dagradi, Peter J Schwartz

Published in: Orphanet Journal of Rare Diseases | Issue 1/2008

Login to get access

Abstract

Congenital long QT syndrome (LQTS) is a hereditary cardiac disease characterized by a prolongation of the QT interval at basal ECG and by a high risk of life-threatening arrhythmias. Disease prevalence is estimated at close to 1 in 2,500 live births.
The two cardinal manifestations of LQTS are syncopal episodes, that may lead to cardiac arrest and sudden cardiac death, and electrocardiographic abnormalities, including prolongation of the QT interval and T wave abnormalities. The genetic basis of the disease was identified in the mid-nineties and all the LQTS genes identified so far encode cardiac ion channel subunits or proteins involved in modulating ionic currents. Mutations in these genes (KCNQ1, KCNH2, KCNE1, KCNE2, CACNA1c, CAV3, SCN5A, SCN4B) cause the disease by prolonging the duration of the action potential. The most prevalent LQTS variant (LQT1) is caused by mutations in the KCNQ1 gene, with approximately half of the genotyped patients carrying KCNQ1 mutations.
Given the characteristic features of LQTS, the typical cases present no diagnostic difficulties for physicians aware of the disease. However, borderline cases are more complex and require the evaluation of various electrocardiographic, clinical, and familial findings, as proposed in specific diagnostic criteria. Additionally, molecular screening is now part of the diagnostic process.
Treatment should always begin with β-blockers, unless there are valid contraindications. If the patient has one more syncope despite a full dose β-blockade, left cardiac sympathetic denervation (LCSD) should be performed without hesitation and implantable cardioverter defibrillator (ICD) therapy should be considered with the final decision being based on the individual patient characteristics (age, sex, clinical history, genetic subgroup including mutation-specific features in some cases, presence of ECG signs – including 24-hour Holter recordings – indicating high electrical instability).
The prognosis of the disease is usually good in patients that are correctly diagnosed and treated. However, there are a few exceptions: patients with Timothy syndrome, patients with Jervell Lange-Nielsen syndrome carrying KCNQ1 mutations and LQT3 patients with 2:1 atrio-ventricular block and very early occurrence of cardiac arrhythmias.
Appendix
Available only for authorised users
Literature
1.
Schwartz PJ, Periti M, Malliani A: The long Q-T syndrome. Am Heart J. 1975, 89: 378-390. 10.1016/0002-8703(75)90089-7.CrossRefPubMed
2.
Jervell A, Lange-Nielsen F: Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death. Am Heart J. 1957, 54: 59-68. 10.1016/0002-8703(57)90079-0.CrossRefPubMed
3.
Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, Shkolnikova M, Berul CI, Bitner-Glindzicz M, Toivonen L, Horie M, Schulze-Bahr E, Denjoy I: The Jervell and Lange-Nielsen Syndrome. Natural history, molecular basis, and clinical outcome. Circulation. 2006, 113: 783-790. 10.1161/CIRCULATIONAHA.105.592899.CrossRefPubMed
4.
Romano C, Gemme G, Pongiglione R: Aritmie cardiache rare dell'età pediatrica. Clin Pediat. 1963, 45: 656-683.
5.
Ward OC: A new familial cardiac syndrome in children. J Ir Med Assoc. 1964, 54: 103-106.PubMed
6.
Nemec J, Hejilik JB, Shen WK, Ackerman MJ: Cathecolamine-induced T-wave lability in congenital long QT syndrome: a novel phenomenon associated with syncope and cardiac arrest. Mayo Clin Proc. 2003, 78: 40-50.CrossRefPubMed
7.
Moss AJ, Robinson JL: The long QT syndrome. Circulation. 2002, 105: 784-786. 10.1161/hc0702.105125.CrossRef
8.
Chiang CE, Roden DM: The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000, 36: 1-12. 10.1016/S0735-1097(00)00716-6.CrossRefPubMed
9.
Stramba-Badiale M, Crotti L, Goulene K, Pedrazzini M, Mannarino S, Salice P, Bosi G, Nespoli L, Rimini A, Gabbarini F, Rosati E, Schwartz PJ: Electrocardiographic and genetic screening for long QT syndrome: results from a prospective study on 44,596 neonates. Circulation. 2007, 116 (Abstr Suppl): II377-
10.
Schwartz PJ, Garson A, Paul T, Stramba-Badiale M, Vetter VL, Wren C, European Society of Cardiology: Guidelines for the interpretation of the neonatal electrocardiogram. A task force of the European Society of Cardiology. Eur Heart J. 2002, 23: 1329-1344. 10.1053/euhj.2002.3274.CrossRefPubMed
11.
Schwartz PJ: The long QT syndrome. Sudden Death. Edited by: Kulbertus HE, Wellens HJJ. 1980, M Nijhoff, The Hague, 358-378.CrossRef
12.
Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999, 99: 529-533.CrossRefPubMed
13.
Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D: Risk stratification in the long-QT syndrome. N Engl J Med. 2003, 348: 1866-1874. 10.1056/NEJMoa022147.CrossRefPubMed
14.
Viskin S, Alla SR, Barron HV, Heller K, Saxon L, Kitzis I, Hare GF, Wong MJ, Lesh MD, Scheinman MM: Mode of onset of torsade de pointes in congenital long QT syndrome. J Am Coll Cardiol. 1996, 28: 1262-1268. 10.1016/S0735-1097(96)00311-7.CrossRefPubMed
15.
Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R: Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001, 103: 89-95.CrossRefPubMed
16.
Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, Schwartz PJ, Andrews M: Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998, 97: 451-456.CrossRefPubMed
17.
Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ: Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004, 1: 60-64. 10.1016/j.hrthm.2004.01.006.CrossRefPubMed
18.
Heradien MJ, Goosen A, Crotti L, Durrheim G, Corfield V, Brink PA, Schwartz PJ: Does pregnancy increase cardiac risk for LQT1 patients?. J Am Coll Cardiol. 2006, 48: 1410-1415. 10.1016/j.jacc.2006.05.060.CrossRefPubMed
19.
Merri M, Benhorin J, Alberti M, Locati E, Moss AJ: Electrocardiographic quantitation of ventricular repolarization. Circulation. 1989, 80: 1301-1308.CrossRefPubMed
20.
Stramba-Badiale M, Spagnolo D, Bosi G, Schwartz PJ: Are gender differences in QTc present at birth? MISNES Investigators. Multicenter Italian Study on Neonatal Electrocardiography and sudden infant death syndrome. Am J Cardiol. 1995, 75: 1277-1278. 10.1016/S0002-9149(99)80780-2.CrossRefPubMed
21.
Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A: The long QT syndrome. prospective longitudinal study of 328 families. Circulation. 1991, 84: 1136-1144.CrossRefPubMed
22.
Schwartz PJ: Idiopathic long QT syndrome: Progress and questions. Am Heart J. 1985, 109: 399-411. 10.1016/0002-8703(85)90626-X.CrossRefPubMed
23.
Vincent GM, Timothy KW, Leppert M, Keating M: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992, 327: 846-852.CrossRefPubMed
24.
Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Geldenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, Roden DM, George AL, Schwartz PJ: Phenotypic variability and unusual clinical severity of congenital long QT syndrome in a founder population. Circulation. 2005, 112: 2602-2610. 10.1161/CIRCULATIONAHA.105.572453.CrossRefPubMed
25.
Schwartz PJ, Vanoli E, Crotti L, Spazzolini C, Goosen A, Hedley P, Heradien M, Bacchini S, Turco A, La Rovere MT, Bartoli A, George AL, Brink PA: Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome. J Am Coll Cardiol. 2008, 51: 920-929. 10.1016/j.jacc.2007.09.069.CrossRefPubMed
26.
Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Coumel P, Petit C, Schwartz K, Guicheney P: A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997, 15: 186-189. 10.1038/ng0297-186.CrossRefPubMed
27.
Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hordt M, Towbin JA, Borggrefe M, Assmann G, Qu X, Somberg JC, Breithardt G, Oberti C, Funke H: KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet. 1997, 17: 267-268. 10.1038/ng1197-267.CrossRefPubMed
28.
Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995, 80: 805-811. 10.1016/0092-8674(95)90359-3.CrossRefPubMed
29.
Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995, 80: 795-803. 10.1016/0092-8674(95)90358-5.CrossRefPubMed
30.
Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996, 12: 17-23. 10.1038/ng0196-17.CrossRefPubMed
31.
Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003, 421: 634-639. 10.1038/nature01335.CrossRefPubMed
32.
Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL, Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Ptacek LJ: Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001, 105: 511-519. 10.1016/S0092-8674(01)00342-7.CrossRefPubMed
33.
Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, George AL, Horie M, Andelfinger G, Snow GL, Fu YH, Ackerman MJ, Vincent GM: Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation. 2005, 111: 2720-2726. 10.1161/CIRCULATIONAHA.104.472498.CrossRefPubMed
34.
Zhou Z, Gong Q, Epstein ML, January CT: HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem. 1998, 273: 21061-21066. 10.1074/jbc.273.33.21061.CrossRefPubMed
35.
Bennett PB, Yazawa K, Makita N, George AL: Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995, 376: 683-685. 10.1038/376683a0.CrossRefPubMed
36.
Medeiros Domingo A, Kaku T, Tester DJ, Iturralde Torres P, Itty A, Ye B, Valdivia CR, Makielski JC, Canizales Quinteiro S, Tusie Luna T, Ackerman MJ: Sodium channel β4 subunit mutation causes congenital long QT syndrome. Heart Rhythm. 2006, 3 (May Suppl): S34-10.1016/j.hrthm.2006.02.117.CrossRef
37.
Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT: Cav 1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004, 119: 19-31. 10.1016/j.cell.2004.09.011.CrossRefPubMed
38.
Ye B, Tester DJ, Vatta M, Makielski JC, Ackerman MJ: Molecular and functional characterization of novel CAV3-encoded caveolin-3 mutations in congenital long QT syndrome. Heart Rhythm. 2006, 3 (May Suppl): S1-10.1016/j.hrthm.2006.02.022.CrossRef
39.
Cronk LB, Ye B, Tester DJ, Vatta M, Makielski JC, Ackerman MJ: Identification of CAV3-encoded caveolin-3 mutations in sudden infant death Syndrome. Heart Rhythm. 2006, 3 (May Suppl): S66-10.1016/j.hrthm.2006.02.210.CrossRef
40.
Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Wang DW, Rhodes TE, George AL, Schwartz PJ: Prevalence of long QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007, 115: 361-367. 10.1161/CIRCULATIONAHA.106.658021.CrossRefPubMed
41.
Schwartz PJ, Moss AJ, Vincent GM, Crampton RS: Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993, 88: 782-784.CrossRefPubMed
42.
Schwartz PJ: The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med. 2006, 259: 39-47. 10.1111/j.1365-2796.2005.01583.x.CrossRefPubMed
43.
Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P: KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997, 96: 2778-2781.CrossRefPubMed
44.
Piippo K, Swan H, Pasternack M, Chapman H, Paavonen K, Viitasalo M, Toivonen L, Kontula K: A founder mutation of the potassium channel KCNQ1 in long QT syndrome: implications for estimation of disease prevalence and molecular diagnostics. J Am Coll Cardiol. 2001, 37: 562-568. 10.1016/S0735-1097(00)01124-4.CrossRefPubMed
45.
Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, Towbin JA, Keating MT, Priori SG, Schwartz PJ, Vincent GM, Robinson JL, Andrews ML, Feng C, Hall WJ, Medina A, Zhang L, Wang Z: Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 2002, 105: 794-799. 10.1161/hc0702.105124.CrossRefPubMed
46.
Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S, Miyamoto Y, Goldenberg I, Andrews ML, McNitt S: Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007, 115: 2481-2489. 10.1161/CIRCULATIONAHA.106.665406.PubMedCentralCrossRefPubMed
47.
Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, Zaklyazminskaya EV, Swan H, Ackerman MJ, Moss AJ, Wilde AA, Horie M, Brink PA, Insolia R, De Ferrari GM, Crimi G: The common Long QT Syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007, 116: 2366-2375. 10.1161/CIRCULATIONAHA.107.726950.CrossRefPubMed
48.
Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, Vicentini A, Yang P, Roden DM, George AL, Schwartz PJ: KCNH2-K897T is a genetic modifier of latent congenital long QT syndrome. Circulation. 2005, 112: 1251-1258. 10.1161/CIRCULATIONAHA.105.549071.CrossRefPubMed
49.
Rubart M, Zipes DP: Genes and cardiac repolarization. The challenge ahead. Circulation. 2005, 112: 1242-1244. 10.1161/CIRCULATIONAHA.105.563015.CrossRefPubMed
50.
Schwartz PJ, Southall DP, Valdes-Dapena M, Eds: The sudden infant death syndrome: cardio-respiratory mechanisms and interventions. Ann NY Acad Sci. 1988, 533: 474-
51.
Schwartz PJ: Cardiac sympathetic innervation and the sudden infant death syndrome. A possible pathogenetic link. Am J Med. 1976, 60: 167-172. 10.1016/0002-9343(76)90425-3.CrossRefPubMed
52.
Maron BJ, Clark CE, Goldstein RE, Epstein SE: Potential role of QT interval prolongation in sudden infant death syndrome. Circulation. 1976, 54: 423-430.CrossRefPubMed
53.
Schwartz PJ, Stramba-Badiale M, Segantini A, Austoni P, Bosi G, Giorgetti R, Grancini F, Marni ED, Perticone F, Rosti D, Salice P: Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med. 1998, 338: 1709-1714. 10.1056/NEJM199806113382401.CrossRefPubMed
54.
Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, Stramba-Badiale M, Richard TA, Berti MR, Bloise R: A molecular link between the sudden infant death syndrome and the long QT syndrome. N Engl J Med. 2000, 343: 262-267. 10.1056/NEJM200007273430405.CrossRefPubMed
55.
Schwartz PJ, Priori SG, Bloise R, Napolitano C, Ronchetti E, Piccinini A, Goj C, Breithardt G, Schulze-Bahr E, Wedekind H, Nastoli J: Molecular diagnosis in a child with sudden infant death syndrome. Lancet. 2001, 358: 1342-1343. 10.1016/S0140-6736(01)06450-9.CrossRefPubMed
56.
Ackerman MJ, Siu BL, Sturner WQ, Tester DJ, Valdivia CR, Makielski JC, Towbin JA: Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA. 2001, 286: 2264-2269. 10.1001/jama.286.18.2264.CrossRefPubMed
57.
Wang DW, Desai RR, Crotti L, Arnestad M, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Rognum T, Schwartz PJ, George AL: Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation. 2007, 115: 368-376. 10.1161/CIRCULATIONAHA.106.646513.CrossRefPubMed
58.
Rhodes TE, Abraham RL, Welch RC, Vanoye CG, Crotti L, Arnestad M, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Rognum T, Roden DM, Schwartz PJ, George AL: Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol. 2008, 44: 571-581. 10.1016/j.yjmcc.2007.11.015.PubMedCentralCrossRefPubMed
59.
Schwartz PJ: Newborn ECG screening to prevent sudden cardiac death. Heart Rhythm. 2006, 11: 1353-1355. 10.1016/j.hrthm.2006.07.016.CrossRef
60.
van Langen IM, Wilde AA: Newborn screening to prevent sudden cardiac death?. Heart Rhythm. 2006, 3: 1356-1359. 10.1016/j.hrthm.2006.07.015.CrossRefPubMed
61.
Quaglini S, Rognoni C, Spazzolini C, Priori SG, Mannarino S, Schwartz PJ: Cost-effectiveness of neonatal ECG screening for the Long QT Syndrome. Eur Heart J. 2006, 15: 1824-1832. 10.1093/eurheartj/ehl115.CrossRef
62.
Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML: Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000, 101: 616-623.CrossRefPubMed
63.
Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J: Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004, 292: 1341-1344. 10.1001/jama.292.11.1341.CrossRefPubMed
64.
Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, Crotti L, Piippo K, Lupoglazoff JM, Villain E, Priori SG, Napolitano C, Zhang L: High efficacy of beta-blockers in long QT syndrome type 1 and identification of the causes underlying events despite therapy.
65.
Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D: Left cardiac sympathetic denervation in the management of high-risk patients affected by the long QT-syndrome. Circulation. 2004, 109: 1826-1833. 10.1161/01.CIR.0000125523.14403.1E.CrossRefPubMed
66.
Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U: Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991, 84: 503-511.CrossRefPubMed
67.
Schwartz PJ, Motolese M, Pollavini G, Lotto A, Ruberti U, Trazzi R, Bartorelli C, Zanchetti A, the Italian Sudden Death Prevention Group: Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. 1992, 3: 2-16. 10.1111/j.1540-8167.1992.tb01090.x.CrossRef
68.
Wilde AAM, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, Ferrandi C, Koolbergen DR, Odero A, Schwartz PJ: Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008, 358: 2024-2029. 10.1056/NEJMoa0708006.CrossRefPubMed
69.
Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M: Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003, 14: 337-341. 10.1046/j.1540-8167.2003.02545.x.CrossRefPubMed
70.
Crotti L, Spazzolini C, De Ferrari GM, Landolina M, Bloise R, Napolitano C, Monnig G, Brugada P, Toivonen L, Hohnloser SH, Tukkie R, Wilde AA, Priori SG, Schwartz PJ: Is the implantable defibrillator appropriately used in the long QT syndrome? Data from the European Registry. Heart Rhythm. 2004, 1 (Suppl): 582-
71.
Etheridge SP, Sanatani S, Cohen MI, Albaro CA, Saarel EV, Bradley DJ: Long QT Syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol. 2007, 50: 1335-1340. 10.1016/j.jacc.2007.05.042.CrossRefPubMed
72.
Wolf MJ, Zeltser IJ, Salerno J, Villafane J, Crosson J, Scott W, Ross B, seaman L, Stephenson E, Paul T, Lau Y, Pandurangi U, Rhodes LA, Kaltman JR, Tanelb RE, Vetter VL, Buck K, Shah MJ: Electrical storm in children with an implantable cardioverter defibrillator: clinical features and outcome. Heart Rhythm. 2007, 4 (May Suppl): S43-
73.
Wilde AA, Jongbloed RJ, Doevendans PA, Düren DR, Hauer RN, van Langen IM, van Tintelen JP, Smeets HJ, Meyer H, Geelen JL: Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol. 1999, 33: 327-332. 10.1016/S0735-1097(98)00578-6.CrossRefPubMed
74.
Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LS: Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995, 92: 3381-3386.CrossRefPubMed
75.
Schwartz PJ: Management of the long QT syndrome. Nat Clin Pract Cardiovasc Med. 2005, 2: 346-351. 10.1038/ncpcardio0239.CrossRefPubMed
76.
Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG: Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007, 116: 1137-1144. 10.1161/CIRCULATIONAHA.107.707877.CrossRefPubMed
77.
Wang DW, Crotti L, Ferrandi C, Rhodes TH, Cantù F, De Filippo P, Schwarz PJ, George AL: Highly malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional SCN5A mutation successfully treated with mexiletine and propranolol. Circulation. 2007, 116 (Abstr Suppl): II54-II55.
78.
Schwartz PJ, Crotti L: Long QT and short QT syndromes. Cardiac Electrophysiology. From Cell to bedside. Edited by: Zipes DP, Jalife J. Elsevier, Philadelphia, PA, USA, 5,
79.
Metadata
Title
Congenital long QT syndrome
Authors
Lia Crotti
Giuseppe Celano
Federica Dagradi
Peter J Schwartz
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2008
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-3-18

Other articles of this Issue 1/2008

Orphanet Journal of Rare Diseases 1/2008 Go to the issue

Research

The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK

Review

Acromegaly

Review

Cluster headache

Review

Centronuclear (myotubular) myopathy

Review

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences

Review

Gitelman syndrome